Home » Healthcare » Pharmaceuticals » Neuroendocrine Tumor Treatment Market

Neuroendocrine Tumor Treatment Market By Drug Class (Everolimus, Sunitinib, Lu-Dotatate, Lanreotide And Octreotide) – Growth, Future Prospects & Competitive Analysis, 2017 – 2025

Price: $4999

Published: | Report ID: 14492 | Report Format : PDF

Market Insights

The 2013 World Trade Center Health Program report on monitoring and treatment furnishes the distribution of neuroendocrine neoplasms in the human body, which is 67.5% in gastrointestinal tracts and 25.3% in the bronchopulmonary tract. According to the World Health Organization, the global incidence rate of malignant neuroendocrine tumours is 0.2 per 100,000 people. Sulfatinib, Vandetanib, and Fotemustine are among the drugs in phase III clinical trials that are being developed as molecularly targeted therapies.The radiopharmaceutical developed as a somatostatin receptor antagonist is 177Lu-edotreotide PRRT.

The drug class segment for the scope of the report on the neuroendocrine tumour treatment market comprises drugs such as Everolimus, Lu-Dotatate, Sunitinib, Lanreotide, and Octreotide. The product pipeline is also covered in the drug class segment, which highlights phase III drugs and provides a tabular representation of phase II and I drugs.Data forecast and market estimation provide the performance of the neuroendocrine tumour treatment market in the geographical segment.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

CTA Design Element 3

Company profiles of the eminent players considered for the scope of the report give important information regarding the existing product portfolio. Recent news coverage provides updates on the status of drugs in the pipeline that have been tested for drug efficacy and safety in clinical trials studies.The competitive landscape gives a gist of the competitive nature of key players present in the neuroendocrine tumour treatment market. Data on the top three countries and attractive investment propositions provides industry investors with an understanding of the market trends present in the attractive markets.The market leaders engaged in the manufacturing of drugs for the treatment of neuroendocrine tumours are Exelixis, Inc., Advanced Accelerator Applications, Dauntless Pharmaceuticals, Inc., Hutchinson Medipharma Limited, Aspen, Novartis AG, Progenics Pharmaceuticals, Inc., and Tarveda Therapeutics.

Based on drug class, the neuroendocrine tumour treatment market is categorised into:

  • MTOR protein inhibitors (Everolimus)
  • Tyrosine kinase 3 inhibitors (Sunitinib)
  • Somatostatin receptor antagonists (Lu-Dotatate)
  • Growth hormone-releasing factor antagonists (lanreotide)
  • Somatostatin receptor agonists (octreotide)
  • Pipeline Analysis
  • Drugs in Phase III
  • Vandetanib
  • Ipilimumab and Fotemustine
  • 177Lu-edotreotide PRRT
  • Sulfatinib
  • Tabular Representation of Phase II and I Drugs

The clinical manifestation of a neuroendocrine tumour suggests that it is benign and sometimes malignant. It is asymptomatic in nature and usually occurs in the gastrointestinal tracts, pancreas, lungs, and other parts of the body. The drug therapy employed for the treatment of neuroendocrine tumours consists of targeted drug therapy and somatostatin analogues. Targeted drug therapy comprises molecules such as everolimus and sunitinib. They are gaining demand in neuroendocrine tumour treatment as they are specifically blocking the growth of cancer by interfering with specific molecules that are engaged in the spread of cancer.

The advantages of targeted drug therapy are that it has fewer side effects in comparison to chemotherapy drugs and is suitable for long-term treatment of chronic conditions. Somatostatin analogues such as Lu-Dotatate and Octreotide represent a futuristic trend in the treatment of neuroendocrine tumors. They are considered viable options for patients resistant to surgery and radiation therapy. The prominent players in the neuroendocrine tumour treatment market are Advanced Accelerator Applications, Dauntless Pharmaceuticals, Inc., Exelixis, Inc., Hutchinson Medipharma Limited, Ispen, Novartis AG, Progenics Pharmaceuticals, Inc., and Tarveda Therapeutics.

For the purpose of this study, the global neuroendocrine tumour treatment market is categorised into the following regional and country-specific markets:

North America

  • United States
  • Canada

Europe

  • United Kingdom
  • Germany
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • rest of Latin America

Middle East and Africa

  • GCC
  • Rest of the Middle East and Africa

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

According to the Centers for Disease Control and Prevention’s 2013 report, the incidence rate of gastrointestinal neuroendocrine neoplasms in the US population is 1.4 cases per 100,000 people. Well-developed diagnostic centres are able to detect asymptomatic neuroendocrine tumors, and expedited drug clearance by the USFDA contributes to the authority of the neuroendocrine tumour treatment drug market in North America. The European market is influenced by the increasing number of patients suffering with pancreatic neuroendocrine tumours and the supportive regulatory environment provided by the European Medical Agency for drugs utilised for neuroendocrine tumour treatment. According to the Asia Pacific Neuroendocrine Tumor Society’s 2017 report, the incidence rate of neuroendocrine tumours in the Asian Pacific population is approximately 1.51 per 100,000 people. An increasing number of cancer treatment centres providing effective diagnosis and treatment are set to propel the Asia-Pacific drug market for the treatment of neuroendocrine tumours.

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Neuroendocrine Tumor Treatment Market Portraiture
2.1.1. Global Neuroendocrine Tumor Treatment Market, by Drug Class, 2016 (Value %)
2.1.2. Global Neuroendocrine Tumor Treatment Market, by Geography, 2016 (Value %)

Chapter 3. Neuroendocrine Tumor Treatment Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Neuroendocrine Tumor Epidemiology Data (Prevalence & Incidence)
3.3. Drivers
3.4. Challenges
3.5. Opportunities
3.6. Attractive Investment Proposition, by Geography
3.7. Top 3 Countries: Global Neuroendocrine Tumor Treatment Market, 2015-2025 (US$ Mn)
3.8. Competitive Landscape: Global Neuroendocrine Tumor Treatment Market, by Key Players, 2015-2025 (US$ Mn)

Chapter 4. Global Neuroendocrine Tumor Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
4.1. Overview
4.2. Attractive Investment Proposition: Global Neuroendocrine Tumor Treatment Market, by Drug Class, 2016
4.3. mTOR protein inhibitors (Everolimus)
4.4. Tyrosine kinase 3 inhibitors (Sunitinib)
4.5. Somatostatin receptor antagonists (Lu-Dotatate)
4.6. Growth hormone releasing factor antagonists (Lanreotide)
4.7. Somatostatin receptor agonists (Octreotide)
4.8. Pipeline Analysis
4.8.1. Phase III Drugs
4.8.1.1. Vandetanib
4.8.1.2. Fotemustine and Ipilimumab
4.8.1.3. 177Lu-edotreotide PRRT
4.8.1.4. Sulfatinib
4.8.2. Tabular Representation of Phase II and I Drugs

Chapter 5. Global Neuroendocrine Tumor Treatment Market, by Geography, 2015 – 2025 (US$ Mn)
5.1. Overview
5.2. North America Neuroendocrine Tumor Treatment Market Analysis, 2015 – 2025
5.2.1. North America Neuroendocrine Tumor Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
5.2.2. North America Neuroendocrine Tumor Treatment Market, by Country, 2015 – 2025 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Neuroendocrine Tumor Treatment Market Analysis, 2015 – 2025
5.3.1. Europe Neuroendocrine Tumor Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
5.3.2. Europe Neuroendocrine Tumor Treatment Market, by Country, 2015 – 2025 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Neuroendocrine Tumor Treatment Market Analysis, 2015 – 2025
5.4.1. Asia Pacific Neuroendocrine Tumor Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
5.4.2. Asia Pacific Neuroendocrine Tumor Treatment Market, by Country, 2015 – 2025 (US$ Mn)
5.4.2.1. Japan
5.4.2.2. China
5.4.2.3. Rest of Asia Pacific
5.5. Latin America Neuroendocrine Tumor Treatment Market Analysis, 2015 – 2025
5.5.1. Latin America Neuroendocrine Tumor Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
5.5.2. Latin America Neuroendocrine Tumor Treatment Market, by Country, 2015 – 2025 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa Neuroendocrine Tumor Treatment Market Analysis, 2015 – 2025
5.6.1. Middle East and Africa Neuroendocrine Tumor Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
5.6.2. Middle East and Africa Neuroendocrine Tumor Treatment Market, by Region, 2015 – 2025 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of Middle East and Africa

Chapter 6. Company Profiles
6.1. Advanced Accelerator Applications
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. Key Developments
6.2. Dauntless Pharmaceuticals, Inc.
6.3. Exelixis, Inc.
6.4. Hutchinson Medipharma Limited
6.5. Ispen
6.6. Novartis AG
6.7. Progenics Pharmaceuticals, Inc.
6.8. Tarveda Therapeutics

List of Figures

FIG. 1 Neuroendocrine Tumor Treatment: Market Segmentation
FIG. 2 Global Neuroendocrine Tumor Treatment Market Share, by Drug Class, 2016 (Value %)
FIG. 3 Global Neuroendocrine Tumor Treatment Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography
FIG. 5 Market Competition Landscape, by Key Players, 2016
FIG. 6 Global Everolimus Drug Market for Neuroendocrine Tumor Treatment, 2015 – 2025 (US$ Mn)
FIG. 7 Global Sunitinib Drug Market for Neuroendocrine Tumor Treatment, 2015 – 2025 (US$ Mn)
FIG. 8 Global Lu-Dotatate Drug Market for Neuroendocrine Tumor Treatment, 2015 – 2025 (US$ Mn)
FIG. 9 Global Lanreotide Drug Market for Neuroendocrine Tumor Treatment, 2015 – 2025 (US$ Mn)
FIG. 10 Global Octreotide Drug Market for Neuroendocrine Tumor Treatment, 2015 – 2025 (US$ Mn)
FIG. 11 U.S. Neuroendocrine Tumor Treatment Market, 2015– 2025 (US$ Mn)
FIG. 12 Canada Neuroendocrine Tumor Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 13 U.K. Neuroendocrine Tumor Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 14 Germany Neuroendocrine Tumor Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 15 Rest of Europe Neuroendocrine Tumor Treatment Market, 2015– 2025 (US$ Mn)
FIG. 16 Japan Neuroendocrine Tumor Treatment Market, 2015– 2025 (US$ Mn)
FIG. 17 China Neuroendocrine Tumor Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 18 India Neuroendocrine Tumor Treatment Market, 2015– 2025 (US$ Mn)
FIG. 19 Rest of Asia Pacific Neuroendocrine Tumor Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 20 Brazil Neuroendocrine Tumor Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 21 Mexico Neuroendocrine Tumor Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 22 Rest of Latin America Neuroendocrine Tumor Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 23 GCC Neuroendocrine Tumor Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 24 Rest of Middle East and Africa Neuroendocrine Tumor Treatment Market, 2015 – 2025 (US$ Mn)

List of Tables

TABLE 1 Global Neuroendocrine Tumor Treatment Market Portraiture
TABLE 2 Global Neuroendocrine Tumor Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 3 Global Neuroendocrine Tumor Treatment Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 4 North America Neuroendocrine Tumor Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 5 North America Neuroendocrine Tumor Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 6 Europe Neuroendocrine Tumor Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 7 Europe Neuroendocrine Tumor Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 8 Asia Pacific Neuroendocrine Tumor Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 9 Asia Pacific Neuroendocrine Tumor Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 10 Latin America Neuroendocrine Tumor Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 11 Latin America Neuroendocrine Tumor Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 12 Middle East And Africa Neuroendocrine Tumor Treatment Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 13 Middle East And Africa Neuroendocrine Tumor Treatment Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 14 Advanced Accelerator Applications: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 Dauntless Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 Exelixis, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 Hutchinson Medipharma Limited: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 Ispen: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 Progenics Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Tarveda Therapeutics: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)

Frequently Asked Questions:

What is the size of Neuroendocrine Tumor Treatment Market?

The market for Neuroendocrine Tumor Treatment Market is expected to reach US$ 1,928.9 Mn By 2025.

What is the Neuroendocrine Tumor Treatment Market CAGR?

The Neuroendocrine Tumor Treatment Market is expected to see significant CAGR growth over the coming years, at 5.73%.

What is the Forecast period considered for Neuroendocrine Tumor Treatment Market?

The report is forecasted from 2017-2025.

What is the base year considered for Neuroendocrine Tumor Treatment Market?

The base year of this report is 2016.

Who are the major players in this market?

Exelixis, Inc., Advanced Accelerator Applications, Dauntless Pharmaceuticals, Inc., Hutchinson Medipharma Limited, Aspen, Novartis AG, Progenics Pharmaceuticals, Inc. are some of the major players in the global market.

Animal Drug Compounding Market

Published:
Report ID: 40870

Antibiotics Market

Published:
Report ID: 40728

Conjugation and Labeling Services Market

Published:
Report ID: 40756

Antiviral Drugs Market

Published:
Report ID: 40681

Intravitreal Injectable Market

Published:
Report ID: 7250

Pharmacogenomics Market

Published:
Report ID: 9486

Nosocomial Infection Treatment Market

Published:
Report ID: 14189

Anti-Cancer Drugs Market

Published:
Report ID: 39971

Vial Adaptors for Reconstitution Drug Market

Published:
Report ID: 15561

Congenital Disabilities Market

Published:
Report ID: 39845

Acquired Hemophilia Treatment Market

Published:
Report ID: 1124

Tyrosine Kinase Inhibitors (TKIs) Market

Published:
Report ID: 39696

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN